Mono Pharmacare Ltd vs Vilin Bio Med Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Mono Pharmacare Ltd is ₹ 13.1 as of 06 May 15:30 . The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 .The P/E Ratio of Vilin Bio Med Ltd is 0 as of March 2023 . The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Vilin Bio Med Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vilin Bio Med Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Vilin Bio Med Ltd

Vilin Bio Med Limited was originally incorporated on June 29, 2005, which commenced business on July 11, 2005 issued by Registrar of Companies, Andhra Pradesh, Hyderabad.
The Company started its first commercial production in 2006.
In 2007, the Company expanded the Phase 2 for Beta Lactum facility with 16000 sft for Tablet, Capsule and Dry Syrup sections.
In 2010, it acquired more than 1000 molecules Drug Approvals with different strengths in therapeutics of Diabetic, Neuro and Cardio. The Company added the Sachet section in Non-Beta Lactum facility in 2014.
The Company allotted a fresh issue of 40,00,000 Equity Shares of Rs 10/- each by its Initial Public Offering by raising funds aggregating to Rs 12 Crore on June 7, 2023. At present, Company is engaged in domestic business of manufacturing Pharmaceuticals products and the Manufacturing Unit is located in Roorkee, in the State of Uttarakhand.

FAQs for the comparison of Mono Pharmacare Ltd and Vilin Bio Med Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Vilin Bio Med Ltd?

Market cap of Mono Pharmacare Ltd is 23 Cr while Market cap of Vilin Bio Med Ltd is 68 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Vilin Bio Med Ltd?

The stock performance of Mono Pharmacare Ltd and Vilin Bio Med Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Vilin Bio Med Ltd?

As of May 6, 2026, the Mono Pharmacare Ltd stock price is INR ₹13.1. On the other hand, Vilin Bio Med Ltd stock price is INR ₹44.85.

How do dividend payouts of Mono Pharmacare Ltd and Vilin Bio Med Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Vilin Bio Med Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.